Glutathione

Overview

Glutathione (GSH) is the body's most abundant endogenous, intracellularly synthesized antioxidant — a tripeptide made of glutamate, cysteine, and glycine, produced in essentially every cell, with particularly high concentrations in the liver. It plays a central role in neutralizing reactive oxygen species, detoxifying xenobiotics through glutathione-S-transferase conjugation, regenerating other antioxidants like vitamins C and E, and supporting immune cell function.

Clinically, glutathione is administered through three routes with meaningfully different evidence bases: oral supplementation (bioavailability was historically questioned, but genuine controlled human trial data now exist), intravenous infusion (widely used in cosmetic and wellness clinics for skin-lightening and general "detox," with a considerably thinner modern trial base for those specific claims), and its precursor N-acetylcysteine (NAC), which has the most extensive, well-established clinical evidence of the three — including FDA approval for acetaminophen overdose.

Also known as: L-glutathione (reduced form, GSH); N-acetyl-L-cysteine (NAC), its precursor. Trade names: Acetadote and Cetylev are FDA-approved NAC products; no FDA-approved glutathione injectable exists for cosmetic or general wellness use in the US. Glutathione itself, oral or IV, is not FDA-approved for skin-lightening, "detox," or general wellness indications — oral glutathione is sold and regulated as a dietary supplement under DSHEA, and IV glutathione is typically a compounded preparation provided under physician order.

How it works

Glutathione exists in reduced (GSH) and oxidized (GSSG) forms; the GSH:GSSG ratio is a commonly used marker of cellular oxidative stress. GSH neutralizes reactive oxygen and nitrogen species directly, and serves as the substrate for glutathione peroxidase (reducing hydrogen peroxide and lipid peroxides) and glutathione-S-transferase (conjugating and detoxifying electrophilic xenobiotics and drug metabolites — including the toxic acetaminophen metabolite NAPQI). It also participates in the ascorbate-glutathione cycle, helping regenerate oxidized vitamin C.

Orally ingested glutathione is substantially degraded by intestinal gamma-glutamyltranspeptidase before absorption, which historically led many researchers to assume oral GSH was ineffective at raising body stores. This is why NAC — a smaller, more bioavailable cysteine donor — became the preferred precursor-based strategy for boosting intracellular GSH synthesis. NAC's own oral bioavailability is also low, roughly 4–10%, attributed to deacetylation in the intestinal mucosa and lumen, though this is sufficient to be clinically effective for its approved indications.³ Administration routes include oral capsules or liposomal formulations, intravenous infusion, and intramuscular or subcutaneous injection in some cosmetic-medicine settings; NAC is additionally available by inhalation as a mucolytic.

What the research shows

Animal / preclinical evidence

The mechanistic rationale for glutathione's use in skin-lightening comes from its role as a substrate that shifts melanin synthesis from darker eumelanin toward lighter pheomelanin via tyrosinase inhibition — a pathway studied mostly in vitro and in dermatology-focused literature rather than large preclinical animal-outcome studies.

Human evidence

The best-designed modern oral glutathione trial is Richie et al. (2015): a double-blind, placebo-controlled trial in 54 healthy non-smoking adults over six months, testing oral GSH at 250 mg/day or 1000 mg/day. This specifically refuted the older assumption that oral GSH is not bioavailable — GSH levels rose 17–35% in blood, erythrocytes, plasma, and lymphocytes, and 260% in buccal cells in the high-dose group (p<0.05), with a corresponding decrease in the oxidized-to-reduced glutathione ratio and more than a 2-fold increase in natural killer cell cytotoxicity at three months in the high-dose group. Levels returned to baseline after a one-month washout.¹ This shows genuine biomarker changes, though it does not establish clinical disease-outcome benefit.

A systematic review and meta-analysis of seven randomized controlled trials (n=450 total) in Parkinson's disease found glutathione produced a statistically significant improvement in motor scores (UPDRS III, standardized mean difference -0.48, 95% CI -0.88 to -0.08, p=0.02) and glutathione peroxidase activity, but no significant difference in other UPDRS subscales or in adverse events between groups.² The authors concluded glutathione "may mildly improve motor scores in PD" — a real but modest signal specific to Parkinson's disease, not a general-wellness finding.

NAC's most clinically validated role uses the precursor rather than glutathione itself: it's FDA-approved (Acetadote) as the antidote for acetaminophen overdose, replenishing depleted hepatic glutathione stores to detoxify the reactive NAPQI metabolite — the single most clinically validated, life-saving application of the glutathione-synthesis pathway.³

Glutathione, oral and IV, is very widely marketed — particularly in parts of Asia — for skin lightening. Some small trials, mostly in dermatology and cosmetic journals with modest sample sizes, report modest skin-lightening effects with oral or topical glutathione over weeks to months, but the evidence for IV glutathione specifically for this purpose is thinner, less rigorously controlled, and has drawn safety warnings in some countries (see Safety, below). There is no robust randomized controlled trial evidence supporting IV glutathione for generalized "detoxification" — this is a wellness-industry marketing claim not tied to a validated clinical endpoint; the liver's endogenous glutathione-based detoxification pathways function continuously regardless of exogenous glutathione infusion in people without a demonstrated deficiency state.

Typical use and dosing

The ranges below reflect published trials and clinical/FDA-labeled practice — presented for education, not as a prescribing recommendation.

Safety, side effects, and who should avoid it

Oral glutathione and NAC are the better-characterized forms: generally well tolerated, with mild GI upset (nausea, bloating) the most common complaint. The Richie 2015 trial reported no significant excess adverse events versus placebo at either dose over six months.¹ The IV kidney and skin safety signal above is specific to the injectable cosmetic-use context and is distinct from the oral supplement safety profile.

Contraindications include known hypersensitivity to the compound, and caution in patients with asthma for inhaled NAC due to bronchospasm risk. IV glutathione should be used cautiously, if at all, in patients with kidney disease given the case-report signal above. NAC may reduce the efficacy of nitroglycerin via nitrate tolerance mechanisms, and has been studied for interactions with certain chemotherapy agents given its antioxidant effect on oxidative-stress-dependent drug mechanisms. No standardized monitoring protocol exists for wellness-clinic IV glutathione use; clinicians using it off-label for cosmetic purposes should consider baseline and periodic renal and thyroid function testing given the case-report safety signals.

Regulatory status

No FDA-approved glutathione injectable exists for cosmetic, wellness, or "detox" indications; IV glutathione used in US clinics for these purposes is a compounded product. Glutathione is not on the FDA's 503A Category 2 restricted-compounding list — unlike BPC-157, CJC-1295, or ipamorelin — which reflects that it hasn't gone through the same nomination-and-review process as those peptides, rather than an affirmative safety endorsement.⁴

NAC is FDA-approved — Acetadote for IV use in acetaminophen toxicity, Cetylev as an oral solution for the same indication, and separately as an inhaled mucolytic — the one component of this compound class with unambiguous FDA approval. Oral NAC's status as a dietary supplement has had periods of regulatory ambiguity in the US, since it was first developed and approved as a drug before being marketed as a supplement; the FDA has at times taken enforcement positions on NAC supplement marketing, though enforcement discretion has generally allowed continued over-the-counter sales.

No major medical specialty society has issued a formal clinical practice guideline endorsing IV glutathione for cosmetic skin-lightening or general wellness/detox use. Some national drug regulatory authorities outside the US — including the Philippines' FDA and health ministries in several other Asian countries where cosmetic glutathione injection is common — have issued specific public health warnings against high-dose IV glutathione injections for skin whitening, citing the kidney and skin adverse-event signal described above; these are safety communications, not endorsements, and cut against marketing claims.³ NAC's role as an acetaminophen antidote is supported by toxicology and emergency medicine clinical practice guidelines, the one area of genuinely guideline-endorsed glutathione-pathway therapy. Neither glutathione nor NAC appears on the WADA Prohibited List — neither is banned in competitive sport.⁵

Frequently asked questions